A First-In-Human (FIH) Clinical Trial of APP13007 for the Treatment of Post-Operative Inflammation of the Eye

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
18 Jul 2019 According to a Sosei Heptares media release, Formosa Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for APP13007 to commence this first-in-human (FIH) clinical trial in the United States. This milestone has triggered a US dollar 2.5 million payment to Sosei Heptares from Formosa.
18 Jul 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com